- Home
- FMAO vs PVLA Comparison
FMAO vs PVLA Comparison
Compare FMAO & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- PVLA
- Stock Information
- Founded
- FMAO 1897
- PVLA 2015
- Country
- FMAO United States
- PVLA United States
- Employees
- FMAO N/A
- PVLA N/A
- Industry
- FMAO Savings Institutions
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- PVLA Health Care
- Exchange
- FMAO Nasdaq
- PVLA Nasdaq
- Market Cap
- FMAO 344.8M
- PVLA 308.2M
- IPO Year
- FMAO N/A
- PVLA N/A
- Fundamental
- Price
- FMAO $22.99
- PVLA $26.91
- Analyst Decision
- FMAO Hold
- PVLA Strong Buy
- Analyst Count
- FMAO 1
- PVLA 7
- Target Price
- FMAO $26.00
- PVLA $44.43
- AVG Volume (30 Days)
- FMAO 19.1K
- PVLA 82.7K
- Earning Date
- FMAO 04-30-2025
- PVLA 05-15-2025
- Dividend Yield
- FMAO 3.85%
- PVLA N/A
- EPS Growth
- FMAO 13.49
- PVLA N/A
- EPS
- FMAO 1.90
- PVLA N/A
- Revenue
- FMAO $101,189,000.00
- PVLA N/A
- Revenue This Year
- FMAO N/A
- PVLA N/A
- Revenue Next Year
- FMAO $6.35
- PVLA N/A
- P/E Ratio
- FMAO $12.13
- PVLA N/A
- Revenue Growth
- FMAO 5.74
- PVLA N/A
- 52 Week Low
- FMAO $19.95
- PVLA $6.20
- 52 Week High
- FMAO $34.15
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- FMAO 48.64
- PVLA N/A
- Support Level
- FMAO $20.88
- PVLA N/A
- Resistance Level
- FMAO $22.94
- PVLA N/A
- Average True Range (ATR)
- FMAO 1.09
- PVLA 0.00
- MACD
- FMAO 0.11
- PVLA 0.00
- Stochastic Oscillator
- FMAO 61.16
- PVLA 0.00
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company for Farmers & Merchants Bank of Central California. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.